

# The treatment of medial compartmental knee osteoarthritis (OA) symptoms with the KineSpring™ Unicompartmental Knee Arthroplasty (UKA) System

|                                        |                                                       |                                                              |
|----------------------------------------|-------------------------------------------------------|--------------------------------------------------------------|
| <b>Submission date</b><br>26/06/2009   | <b>Recruitment status</b><br>No longer recruiting     | <input checked="" type="checkbox"/> Prospectively registered |
| <b>Registration date</b><br>14/07/2009 | <b>Overall study status</b><br>Completed              | <input type="checkbox"/> Protocol                            |
| <b>Last Edited</b><br>12/09/2016       | <b>Condition category</b><br>Musculoskeletal Diseases | <input type="checkbox"/> Statistical analysis plan           |
|                                        |                                                       | <input type="checkbox"/> Results                             |
|                                        |                                                       | <input type="checkbox"/> Individual participant data         |
|                                        |                                                       | <input type="checkbox"/> Record updated in last year         |

## Plain English summary of protocol

Not provided at time of registration

## Contact information

### Type(s)

Scientific

### Contact name

Prof James B. Richardson

### Contact details

Institute of Orthopaedics  
Robert Jones and Agnes Hunt Orthopaedic and District Hospital  
Oswestry Outcome Centre  
Oswestry, Shropshire  
United Kingdom  
SY10 7AG

### Type(s)

Scientific

### Contact name

Prof Jan Victor

### Contact details

Department of Orthopaedic Surgery and Traumatology  
University Hospital

University of Gent  
De Pintelaan 185, 1P5  
Gent  
Belgium  
9000

**Type(s)**

Scientific

**Contact name**

Mr Rhys Williams

**Contact details**

University Hospital of Wales  
Cardiff and Vale NHS Trust  
Heath Park  
Cardiff  
United Kingdom  
CF14 4XW

**Type(s)**

Scientific

**Contact name**

Mr Timothy Wilton

**Contact details**

Derbyshire Royal Infirmary  
Derby Hospitals Foundation  
London Road  
Derby  
United Kingdom  
DEL 2QY

**Type(s)**

Scientific

**Contact name**

Mr Nicolas John London

**Contact details**

Harrogate District Hospital  
Harrogate & District NHS Foundation Trust  
Lancaster Park Road  
Harrogate  
United Kingdom  
HG2 7SX

**Type(s)**

Scientific

**Contact name**

Mr Nicolas John London

**Contact details**

The Duchy BMI  
Queens Road  
Harrogate  
United Kingdom  
HG2 0HF

## **Additional identifiers**

**Protocol serial number**

KINE-0902

## **Study information**

**Scientific Title**

A multicentre open-label interventional study of patients with medial compartmental knee osteoarthritis (OA) symptoms treated with the KineSpring™ Unicompartmental Knee Arthroplasty (UKA) System

**Acronym**

COAST

**Study objectives**

The null hypothesis (H0) is that the Knee Society Score (KSS) for function derived from subjects treated with the KineSpring™ UKA System is inferior to a mean KSS for function of 80 which is widely reported in applicable literature:

H0: KSS less than or equal to 80 - d

The alternative hypothesis (H1) is that the KSS for function associated with KineSpring™ UKA System subjects is not inferior:

H1: KSS greater than 80 - d

**Ethics approval required**

Old ethics approval format

**Ethics approval(s)**

1. University of Ghent, Belgium, 07/10/2009
2. Leeds West Research Ethics Committee, UK, 21/10/2009
3. All other centers have received ethics approval before recruitment of the first participant

**Study design**

Prospective multicentre open-label non-randomised non-inferiority study

**Primary study design**

Interventional

**Study type(s)**

## Treatment

### Health condition(s) or problem(s) studied

Osteoarthritis of the knee

### Interventions

Arthroplasty of the knee. There is only one treatment arm as the results of this arm will be compared to a historical control. The surgical procedure lasts 1.5 to 2 hours. Enrolment will take place over 9 months with 24 year follow-up there after, so any one patient will participate in the study for a maximum of 24 months.

### Intervention Type

Procedure/Surgery

### Primary outcome(s)

The KSS Function score 6 months post-KineSpring™ UKA System surgery

### Key secondary outcome(s)

1. Procedural success (i.e., successful implantation of the device)
2. Treatment-emergent AEs at surgery, 2 and 6 weeks, 3, 6, 12, 18, and 24 months (to include device malfunctions/unanticipated adverse device evaluations (UADEs))
3. Subject reported symptom severity changes from baseline measurement at 6 weeks, 3, 6, 12, 18, and 24 months in the following criteria:
  - 3.1. KOOS score
  - 3.2. EuroQol (EQ-5D)
  - 3.3. Lysholm Knee Scale
  - 3.4. Knee Specific Pain Scale
  - 3.5. Investigator's assessment of patients' global status
  - 3.6. Activity Profile
  - 3.7. Patient Overall Treatment Evaluation
4. KSS knee and function scores at 6 weeks, 3, 6, 12, 18, and 24 months
5. KineSpring™ UKA System stability through evaluation of radiographic parameters at 3, 6, 12, and 24 month follow-up

### Completion date

01/01/2014

## Eligibility

### Key inclusion criteria

1. Aged greater than or equal to 25 years, either sex
2. Diagnosis of medial OA of the target knee based on American College of Rheumatology (ACR) Clinical and Radiographic or Clinical Classification criteria for osteoarthritis with a minimum 12 month history
3. Continued knee pain despite minimum 3 months of conservative therapy, (i.e., physical therapy, bracing, orthotics, systemic or injected medications)
4. Knee flexion greater than or equal to 90 degrees
5. KSS knee and function scores less than 70
6. Weight greater than 60 kg
7. Ability to tolerate antibiotics
8. Willing and able to give voluntary written informed consent to participate in this clinical

investigation

9. Prepared to consent to the transfer of his/her information to third parties

10. Willing to undertake the required investigational procedures and willing to return for the required follow-up evaluations

### **Participant type(s)**

Patient

### **Healthy volunteers allowed**

No

### **Age group**

Adult

### **Sex**

All

### **Key exclusion criteria**

1. Active infection, sepsis or osteomyelitis, history of infection in the target knee or distant foci of infections which may spread to the implant site
2. Rheumatoid arthritis or other forms of inflammatory joint disease
3. Significant OA in lateral or patellofemoral compartment
4. Previous surgery in the target knee within 12 months prior to screening
5. Previous osteotomy or failed knee endoprostheses of any kind in the target knee
6. Tibial-femoral varus or valgus alignment greater than 10 degrees
7. Ligamentous or meniscal instability as assessed by the Investigator
8. Concomitant immunosuppressive therapy
9. Paget's disease or metabolic disorders which may impair bone formation
10. Osteomalacia or moderate to severe osteoporosis, rapid joint destruction, marked bone loss or bone resorption noted on x-ray
11. Charcot's joint disease or other severe neurosensory deficits
12. Incomplete or deficient soft tissue surrounding the knee as assessed by the Investigator
13. Flexion deformity greater than 10 degrees
14. Uncontrolled diabetes mellitus or other significant co-morbidities
15. Any significant medical condition (e.g., significant psychiatric or neurological disorders, active alcohol/drug abuse, etc) or other factor (e.g. planned relocation, uncooperative patient) that the Investigator feels would interfere with study participation
16. The patient is pregnant or lactating
17. Historic or ongoing litigation for or participation in workers compensation for musculoskeletal injuries or disorders
18. Subjects who are currently enrolled in another clinical investigation

### **Date of first enrolment**

30/09/2009

### **Date of final enrolment**

01/01/2014

## **Locations**

### **Countries of recruitment**

United Kingdom

England

Belgium

**Study participating centre**

**Robert Jones and Agnes Hunt Orthopaedic and District Hospital**

Oswestry

United Kingdom

SY10 7AG

## **Sponsor information**

**Organisation**

Moximed Inc. (USA)

**ROR**

<https://ror.org/04hrwvd56>

## **Funder(s)**

**Funder type**

Industry

**Funder Name**

Moximed Inc. (USA)

## **Results and Publications**

**Individual participant data (IPD) sharing plan**

**IPD sharing plan summary**

Not provided at time of registration